Adicet Announces Appointment of Katie Peng to the Board of Directors
11 Julho 2023 - 9:30AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced the appointment of Katie Peng
to its Board of Directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230711946213/en/
Katie Peng, Board of Directors, Adicet
Bio, Inc. (Photo: Business Wire)
“We are delighted to welcome Katie to our Board of Directors,”
said Chen Schor, President and Chief Executive Officer of Adicet
Bio. “Her proven success as a commercial leader in both the U.S.
and globally will be particularly valuable to Adicet as we advance
ADI-001 and our pipeline of allogeneic gamma delta T cell therapy
candidates in hematologic and solid tumors.”
“I am pleased to join the Adicet Board at this exciting time for
the company,” said Ms. Peng. “As the company advances towards its
potentially pivotal study of ADI-001 in post CAR T large B-cell
lymphoma, I look forward to working with my fellow board members
and company management to prepare Adicet for the potential
commercialization of ADI-001 and other future therapies.”
Ms. Peng brings extensive industry and commercial expertise to
the Board. She currently serves as Chief Commercial Officer at
Denali Therapeutics Inc., where she is leading the global
commercialization efforts of Denali’s pipeline. Previously Ms. Peng
served as the Senior Vice President, Head of the OMNI Business Unit
at Genentech, Inc., where she was responsible for the oncology,
neurology, and rare diseases portfolio representing approximately
$14 billion in revenue, and served as part of Genentech’s
commercial leadership team. Prior to Genentech, Ms. Peng held a
number of senior leadership positions at Roche Holding AG, managing
the Roche portfolio of over 30 products in the Asia Pacific region
as the General Manager of two countries. Ms. Peng has successfully
launched multiple products in neurology, oncology, and rare
disease, notably including OCREVUS® (ocrelizumab), a therapeutic
monoclonal antibody approved for the treatment of multiple
sclerosis, Evrysdi® (risdiplam), a medicine used to treat spinal
muscular atrophy (SMA) in adults and children, and HEMLIBRA®
(emicizumab-kxwh), a bispecific antibody for the treatment of
people with hemophilia A. Her experience spans marketing, sales,
market access, medical affairs and business planning. Before
joining Roche, Ms. Peng held several commercial roles at Amgen Inc.
and began her career as a research scientist at Allergan plc. She
holds a B.A. from the University of California, Berkeley and an
M.B.A. from the Kelley School of Business, Indiana University. She
also serves as a board member for California Life Sciences.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to business and operations of Adicet.
These forward-looking statements include, but are not limited to,
express or implied statements regarding future plans and
expectations for ADI-001 and Adicet’s preclinical programs; the
anticipated timing for the initiation of a potentially pivotal
study for ADI-001; the potential commercialization of Adicet’s
pipeline; Adicet’s expected growth as a company; and the
anticipated contribution of the members of Adicet’s Board of
Directors to the company’s operations and progress.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including without limitation, the effect of COVID-19 on Adicet’s
business and financial results, including with respect to
disruptions to Adicet’s business operations and ability to raise
additional capital; Adicet's ability to execute on its strategy,
including obtaining the requisite regulatory approvals on the
expected timeline, if at all; that positive results from
preclinical studies may not necessarily be predictive of the
results of any future clinical studies; any future preclinical or
clinical studies may fail to demonstrate adequate safety and
efficacy of Adicet’s product candidates, which would prevent,
delay, or limit the scope of regulatory approval and
commercialization; and regulatory approval processes of the U.S.
Food and Drug Administration and comparable foreign regulatory
authorities are lengthy, time-consuming, and inherently
unpredictable. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Adicet's actual results to differ from those contained in the
forward-looking statements, see the section titled "Risk Factors"
in Adicet's most recent Annual Report on Form 10-K for the year
ended December 31, 2022 and subsequent filings with the SEC. All
information in this press release is as of the date of the release,
and Adicet undertakes no duty to update this information unless
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230711946213/en/
Adicet Bio., Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com Janhavi Mohite Stern Investor
Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Adicet Bio (NASDAQ:ACET)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024